Epie Boven
Vrije Universiteit Amsterdam
H-index: 63
Europe-Netherlands
Top articles of Epie Boven
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
306P Multiplexed immunofluorescence (mIF) to select patients with HER2+ breast cancer (BC) having an excellent outcome without chemotherapy (chemo): A substudy of the PERNETTA … | Annals of Oncology | K Zaman S Tissot F Benedetti D Dietrich D Tarussio | 2023/10/1 |
Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial | JAMA oncology | Jens Huober Patrik Weder Karin Ribi Beat Thürlimann Jean-Christophe Thery | 2023/10/1 |
MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer | Journal of Experimental Medicine | Jinhyuk Bhin Julia Yemelyanenko Xue Chao Sjoerd Klarenbeek Mark Opdam | 2023/8/29 |
Plasma ESR1 mutations and outcome to first-line paclitaxel and bevacizumab in patients with advanced ER-positive/HER2-negative breast cancer | Breast cancer research and treatment | MK Bos SW Lam G Motta JCA Helmijr CM Beaufort | 2023/7 |
Genome-Wide Meta-Analysis Identifies Variants in DSCAM and PDLIM3 That Correlate with Efficacy Outcomes in Metastatic Renal Cell Carcinoma Patients … | Cancers | Meta HM Diekstra Jesse J Swen Loes FM van der Zanden Sita H Vermeulen Epie Boven | 2022/6/8 |
685P Genome-wide association meta-analysis identifies novel variants that correlate with efficacy outcomes in sunitinib-treated patients with metastatic renal cell carcinoma | Annals of Oncology | M Diekstra J Swen L van der Zanden S Vermeulen E Boven | 2021/9/1 |
29P Plasma ESR1 mutations and outcome to first-line chemotherapy with bevacizumab and paclitaxel in patients with advanced ER-positive/HER2-negative breast cancer | Annals of Oncology | MK Bos SW Lam JCA Helmijr CM Beaufort A Jager | 2021/5/1 |
Hierarchical clustering of PI3K and MAPK pathway proteins in breast cancer intrinsic subtypes | Apmis | Dinja T Kruger Mark Opdam Joyce Sanders Vincent van der Noort Epie Boven | 2020/4 |
High ctDNA molecule numbers relate with poor outcome in advanced ER+, HER2− postmenopausal breast cancer patients treated with everolimus and exemestane | Molecular oncology | Dinja T Kruger Maurice PHM Jansen Inge RHM Konings Wouter M Dercksen Agnes Jager | 2020/3 |
Visual and quantitative evaluation of [18F]FES and [18F]FDHT PET in patients with metastatic breast cancer: an interobserver variability study | EJNMMI research | Lemonitsa H Mammatas Clasina M Venema Carolina P Schröder Henrica CW de Vet Michel van Kruchten | 2020/12 |
PI3K pathway protein analyses in metastatic breast cancer patients receiving standard everolimus and exemestane | Journal of Cancer Research and Clinical Oncology | Dinja T Kruger Mark Opdam Vincent van der Noort Joyce Sanders Michiel Nieuwenhuis | 2020/11 |
IGF‐1R pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in ER‐positive breast cancer | International journal of cancer | Dinja T Kruger Xanthippi Alexi Mark Opdam Karianne Schuurman Leonie Voorwerk | 2020/4/15 |
